PUBLIC COMPANY
savePATH
updated 5mo ago
community read0 votes
🐶 often sniffed alongside
top 8- tagRecall10 co-mentions · 10 sources
- tagHematology6 co-mentions · 6 sources
- tagAdCom4 co-mentions · 4 sources
- tag510(k) Clearance3 co-mentions · 3 sources
- companyUniversity of Virginia1 co-mentions · 1 sources
- companyUniversity of Washington1 co-mentions · 1 sources
- tagCardiology1 co-mentions · 1 sources
- tagImmunology1 co-mentions · 1 sources
pipeline
1
marketed
0
phase 3
0
catalysts ytd
8
approvals ytd
0
recalls ytd
6
Pipeline(1)
pipeline depth1 products
1Preclinical
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh
- phase2Study of a Novel Type 3 Oral Poliomyelitis Vaccine in Panama
- phase2Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation
- phase2Infant Malaria Vaccine Schedule Optimization
- phase3Phase 3 Trial of a Bivalent Human Papilloma Virus (HPV) Vaccine (Cecolin®) in Young Girls
- phase1Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines
- phase2Study of Malaria Vaccine RTS,S/AS01E in Plasmodium Falciparum-infected and Uninfected Adults Pre-treated With Anti-malarial Therapy
🐶 Hiring Signal
News
- Actinogen’s sole drug fails pivotal Alzheimer’s study, sinking stock 80%Actinogen Medical’s lead program for its sole pipeline candidate has failed a late-stage study, but the Australian biotech still plans on taking the findings to the FDA for a path forward.biospace · 5h ago
- nChroma halves workforce, BioXcel lets execs goFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 5h ago
- With FDA nod, Regeneron brings an RNAi drug to autoimmune diseaseThe product of a collaboration with Alnylam, Livsayis is now Regeneron’s first marketed RNAi drug and will compete against established medicines from AstraZeneca and Argenx.biopharma_dive · 6h ago
- nChroma halves headcount, calls time on trial of potential HBV ‘cure’nChroma Bio’s workforce is facing a second round of layoffs in 12 months, with the Boston biotech halving its headcount and scrapping a trial of its lead hepatitis asset.fiercebiotech · 12h ago
- CTAD 2026: Biogen, AriBio lead the way in slowing cognitive decline in Alzheimer’sBiogen and AriBio reported wins for their respective therapies targeting Alzheimer’s disease, while Priavoid and Cognito Therapeutics missed the mark—though the latter plans to file for FDA approva…biospace · 1d ago
- FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSKThe FDA had several issues with ivonescimab, according to the letter. Elsewhere, Sellas shares rocketed on results for a leukemia vaccine and Biogen and Lilly struck up new R&D pacts.biopharma_dive · 1d ago
- In China’s shadow, Pfizer CEO calls for AI savings to bolster Big PharmaSpeaking at the Jefferies conference in London, Pfizer CEO Albert Bourla warned of China’s rise and spoke to how companies like his can compete by leveraging AI-discovered savings.biospace · 1d ago
- AbbVie busts a move with Disco in $2.5B dance aimed at bispecific discoveryAbbVie is twirling onto the dance floor with Disco Pharmaceuticals, offering up to $2.5 billion to work with the German platform company on cancer-targeted bispecific discovery.fiercebiotech · 1d ago
- Cognito phase 3 flops in light-and-sound Alzheimer's trial, but sees ‘signal’ for HOPECognito Therapeutics said its phase 3 HOPE study of Spectris AD, an investigational, non-invasive, at-home Alzheimer's therapy that uses light and sound stimulation to engage brain activity, failed…fiercebiotech · 1d ago
- Beren wins FDA approval for long-studied rare disease drugA molecule designed by government scientists more than a decade ago has won FDA approval to treat infantile-onset Niemann-Pick disease type C, capping a winding and rocky development path. Beren Th…endpoints · 2d ago
Data sources
Found something off?
comments(0)
5-min edit window · permanent after that